Prime Medicine PRME Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's additional paid-in capital?
- Prime Medicine (PRME) reported additional paid-in capital of $1.01B in Q1 2026.
- How has Prime Medicine's additional paid-in capital changed year-over-year?
- Prime Medicine's additional paid-in capital increased by 19.9% year-over-year, from $846.04M to $1.01B.
- What is the long-term trend for Prime Medicine's additional paid-in capital?
- Over 4 years (2021 to 2025), Prime Medicine's additional paid-in capital has grown at a 185.6% compound annual growth rate (CAGR), from $15.16M to $1.01B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.